PET/CT guided tuberculosis treatment shortening: a randomized trial.
Stephanus T Malherbe,Ray Y Chen,Xiang Yu,Bronwyn Smith,Xin Liu,Jingcai Gao,Andreas H. Diacon,Rodney Dawson,Michele Tameris,Hong Zhu,Yahong Qu,Hongjian Jin,Shouguo Pan,Lori E Dodd,Jing Wang,Lisa C Goldfeder,Ying Cai,Kriti Arora,Joel Vincent,Kim Narunsky,Keboile Serole,Rene Goliath,Laylah Da Costa,Arshad Taliep,Saalikha Aziz,Remy Daroowala,Friedrich Thienemann,Sandra Mukasa,Richard Court,Bianca Sossen,Petri Ahlers,Simon C Mendelsohn,Lisa White,Aurelie Gouel,Chuen-Yen Lau,Samy Hassan,Lili Liang,Hongfei Duan,Gita K Moghaddam,Praveen Paripati,Saher Lahouar,Michael Harris,Kurt Wollenberg,Brendan Jeffrey,Mike Tartakovsky,Alex Rosenthal,Michael Duvenhage,Derek T Armstrong,Taeksun Song,Jill Winter,Qian Gao,Laura E Via,Robert J Wilkinson,Gerhard Walzl,Clifton E Barry III
DOI: https://doi.org/10.1101/2024.10.03.24314723
2024-10-04
Abstract:Six months of chemotherapy using current agents is standard of care for pulmonary, drug-sensitive tuberculosis (TB), even though some are believed to be cured more rapidly and others require longer therapy. Understanding what factors determine the length of treatment required for durable cure in individual patients would allow individualization of treatment durations, provide better clinical tools to determine the of appropriate duration of new regimens, as well as reduce the cost of large Phase III studies to determine the optimal combinations to use in TB control programs. We conducted a randomized clinical trial in South Africa and China that recruited 704 participants with newly diagnosed, drug-sensitive pulmonary tuberculosis and stratified them based on radiographic disease characteristics as assessed by FDG PET/CT scan readers. Participants with less extensive disease (N=273) were randomly assigned to complete therapy after four months or continue receiving treatment for six months. Amongst participants who received four months of therapy, 17 of 141 (12.1%) experienced unfavorable outcomes compared to only 2 of 132 (1.5%) who completed six months of treatment (treatment success 98.4% in B, 86.7% in C (difference -11.7%, 95% CI, -18.2%, -5.3%)). In the non-randomized arm that included participants with more extensive disease, only 8 of 248 (3.2%) experienced unfavorable outcomes. Total cavity volume and total lesion glycolysis at week 16 were significantly associated with risk of unfavorable outcome in the randomized participants. Based on PET/CT scans at TB recurrence, bacteriological relapses (confirmed by whole genome sequencing) predominantly occurred in the same active cavities originally present at baseline. Automated segmentation of the serial PET/CT scans was later performed, and machine-learning was used to classify participants according to their likelihood of relapse, allowing the development of predictive models with good performance based on CT, PET, microbiological and clinical characteristics. These results open the possibility for more efficient studies of future TB treatment regimens.
Infectious Diseases (except HIV/AIDS)